Dec 22 (Reuters) - AlloVir said on Friday it will discontinue three late-stage studies testing its experimental antiviral cell therapy after an independent safety board said the studies were unlikely to meet their main goals. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7689 USD | -0.84% | +2.51% | +13.11% |
May. 13 | AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 20 | North American Morning Briefing : Markets on Hold -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.11% | 87.96M | |
+9.58% | 115B | |
+12.41% | 106B | |
-2.59% | 21.96B | |
-12.38% | 21.87B | |
-5.29% | 19.21B | |
-3.35% | 18.08B | |
-38.57% | 17.71B | |
+7.51% | 14.32B | |
+35.67% | 12.42B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir scraps late-stage studies testing antiviral cell therapy